Job Description

Immix Biopharma, Inc. (NADSAQ:IMMX)

Corporate Strategy – Analyst  

Location: Los Angeles, CA / Hybrid

• Assist with corporate, investor and board presentations
• Assist with financial and operating models
• Existing Pipeline – Using literature and commercial database research, participate in determining development strategy for existing pipeline
• New Pipeline - Conduct literature and commercial database research to evaluate opportunities to expand pipeline of human therapeutics

Prior healthcare investment banking and/or equity research internship, or work experience (~1-2 years) preferred

Full time position

Education: BS/BA, or MD/PhD/PharmD/science degree

About Immix Biopharma, Inc.

Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and autoimmune diseases. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201. NXC-201 is being evaluated in the U.S. Phase 1b/2a trial NEXICART-2 (NCT06097832) as well as the ex-U.S. study NEXICART-1 (NCT04720313). NXC-201 has demonstrated short duration of cytokine release syndrome (CRS) and no grade 3 or delayed neurotoxicity in high-volume disease, as well as short duration CRS and no neurotoxicity of any kind in AL Amyloidosis, supporting expansion into autoimmune indications. NXC-201 has been awarded Orphan Drug Designation (ODD) in the US by the FDA and in the EU by the EMA in AL Amyloidosis.